RBCx features AmacaThera’s journey
RBCx, the tech banking and investment arm of the Royal Bank of Canada, has featured AmacaThera’s drug development platform and start-up journey.
Read more
AmacaThera Announces Close of Oversubscribed Series A Financing
Clinical trials set to begin on their proprietary drug delivery platform addresses key problem in sustained therapeutic delivery and is applicable to numerous disease indications and therapeutic modalities.Read more
Professor Molly Shoichet awarded the Gerzhard Herzberg Canada Gold Medal
Biomedical engineer’s novel hydrogel designs useful for regenerative medicine.Read more
AmacaThera Secures Funding to Initiate Phase I Trial of Non-Opioid Pain Control Therapeutic
AmacaThera, a Toronto-based company commercializing hydrogel-based drug delivery platforms, has already raised $3.25 million (CAD) in seed financing from Sprout BioVentures, Viva Biotech, and Grey Sky Venture Partners.Read more
Ontario Names Molly Shoichet the Province's First Chief Scientist
Shoichet Will Help Accelerate Scientific Innovation and Advance Science in Government Decision-Making.Read more